Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$16.84
Change (%) Stock is Down 0.07 (0.41%)
Volume4,835,380
Data as of 12/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
12/07/16Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and PipelinePrinter Friendly Version
11/30/16Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14Printer Friendly Version
11/21/16Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29Printer Friendly Version
11/07/16Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15Printer Friendly Version
Upcoming EventsMore >>
Exelixis, Inc. at the BMO Capital Markets Prescriptions for Success Healthcare Conference
Wednesday, December 14, 2016 3:40 p.m. ET
Add to Calendar Add Exelixis, Inc. at the BMO Capital Markets Prescriptions for Success Healthcare Conference to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.